



#### FACSIMILE TRANSMISSION SHEET

IN RE APPLICATION OF

ATWAL ET AL.

APPLICATION NO: 10/660,878 FILED: SEPTEMBER 12, 2003

FOR: HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS

DATE OF TRANSMISSION: December 16, 2004

TO: Examiner Deepak Rao

Art Unit 1624

PTO FACSMILE NO: <u>571-273-8300</u>

**NUMBER OF PAGES:** (6, including cover sheet)

INFORMATION DISCLOSURE

STATEMENT

FROM: Bristol-Myers Squibb Company

ATTN: Deanna L. Baxam

**RETURN FACSIMILE NO.:** (609) 252-4526

This communication is being filed in the United States Patent and Trademark Office by facsimile transmission according to the provisions of 37 C.F.R. § 1.6(d). The sender acknowledges that the receipt date accorded to the correspondence will be the date on which the complete transmission is received in the Patent and Trademark Office. As required, the application number of the patent or application is entered as a part of the sender's identification above.

If all pages of this transmission are not received, please immediately contact:

Tina Markee @ (609) 252-4300; or Deanna L. Baxam @ (609) 252-4014.

Encomplete.
page 6 incomplete

### RECEIVED CENTRAL FAX CENTER

10.29% - 2.2

DEC 1 6 2004

CASE HA0726DIV

#### CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below by facsingle transmission to the Official PTO Fax Number, (571) 273-8300.

Deanna Baxam
Type or print name

Signature

12/4/04

nature

Date

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LLOYD ET AL.

APPLICATION NO: 10/660,878 FILED: SEPTEMBER 12, 2003

FOR: HETEROCYCLO DIHYDROPYRIMIDINE COMPOUNDS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

#### Commissioner:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

The Commissioner is authorized to charge any fee deemed necessary, or credit any overpayment thereof, to the assignee's Deposit Account Number 19-3880.

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4014

Date: December 16, 2004

Respectfully submitted,

Deanna L. Baxam Attorney for Applicants Reg. No. 45,266

## INFORMATION DISCLOSURE CHAILON

(Use several shoots it necessary)

S.N. 10,10.29: 178 - 4 Ally Docks+ No. HA776DIV Group 1624

<del></del>			U.S. PA	TENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CI.	ASS SUBCL	uss F	ILING DATE
	AA							
·····	AB							·
	AC					·		
	AD							
	AE							
	AF							
	AG							
	AH							
	Al		·					
	AJ							
	AK							
	AL							
		•						
			FOREIGN	PATENT DOCUMENTS				
	<u> </u>	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM	DOCUMENT NUMBER		····	CLASS	SUBCLASS	TRAN YES	ISLATION NO
	AM	DOCUMENT NUMBER		····	CLASS	SUBCLASS	YES	NO NO
		DOCUMENT NUMBER		····	CLASS	SUBCLASS	YE\$	NO NO
	AN	DOCUMENT NUMBER		····	CLASS	SUBCLASS	YES	NO
	AN AO	DOCUMENT NUMBER		····	CLASS	SUBCLASS	YES	NO
	AN AO AP		DATE	····			YES	NO CONTRACTOR NO
	AN AO AP	OTHER DOCU	JMENTS (Including Selective er of central vo	office cluding Author, Tide, Date, Perl alterations in local cerebra oltage-activated K+-chann	tinent pages, E al glucose ut nels," Eur J N	to.) ilization evok leurosci, 200	YES	NO CONTRACTOR NO
	AN AO AP AQ	OTHER DOCU Cochran et al., "Region charybdotoxin, a block Nov;14(9):1455-63; Coleman et al., "Subur Aug;73(2):849-58;	JMENTS (Including selective er of central voit composition	of Kv1 channels in huma	tinent pages, E al glucose ut els," Eur J N	ito.) ilization evok leurosci. 200 eurochem. 1	PYES	NO
	AN AO AP AQ	OTHER DOCU Cochran et al., "Region charybdotoxin, a block Nov;14(9):1455-63; Coleman et al., "Subur Aug;73(2):849-58;	JMENTS (Including selective er of central voit composition	office cluding Author, Tide, Date, Perl alterations in local cerebra oltage-activated K+-chann	tinent pages, E al glucose ut els," Eur J N	ito.) ilization evok leurosci. 200 eurochem. 1	PYES	NO

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

# DENTE 2004 CHAZAMPATENTANS PATENT DEPTRICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

S.N. 10,29:10,878 5 Ally. Docket No. HA726DIV Group 1624

### OTHER DOCUMENTS (Including Author, Tibe, Date, Pertinent pages, Etc.)

АА	Frey et al., "Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine," Neurogastroenterol Motil. 2000 Dec;12(6):509-16;
ΔR	Hanson et al., "UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

befects in the images include but are not limited to the items checked:
□ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.